When blood coagulation takes place in the presence of calcium ions, a2-plasmin inhibitor (a2PI) is cross-linked to fibrin by activated coagulation Factor XIII (XIIIa) and thereby contributes to the resistance of fibrin to fibrinolysis. It was previously shown that the cross-linking reaction is a reversible one, since the a2PI-fibrinogen cross-linked complex could be dissociated. In the present study we have shown that the a2PI-fibrin cross-linking reaction is also a reversible reaction and a2PI which had been cross-linked to fibrin can be released from fibrin by disrupting the equilibrium, resulting in a decrease of its resistance to fibrinolysis. When the fibrin clot formed from normal plasma in the presence of calcium ions was suspended in a2PI-deficient plasma of buffered saline, a2PI was gradually released from fibrin on incubation. When a2PI was present in the suspending milieu, the release was decreased inversely to the concentrations of a2PI in the suspending milieu. The release was accelerated by supplementing XIIIa or the presence of a high concentration of the NH2-terminal 12-residue peptide of a2PI (N-peptide) which is cross-linked to fibrin in exchange for the release of a2PI. When the release of a2PI from fibrin was accelerated by XIIIa or Npeptide, the fibrin became less resistant to the fibrinolytic process, resulting in an acceleration of fibrinolysis which was proportional to the degree of the release of a2PI. These results suggest the possiblity that a2PI could be released from fibrin in vivo by disrupting the equilibrium of the a2PI-fibrin cross-linking reaction, and that the release would result in accelerated thrombolysis.
Introduction
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1. Abbreviations used in this paper: a2PI, a2-plasmin inhibitor; '251-FDP, radiolabeled fibrin degradation products; N-peptide, the NH2-terminal 12-residue peptide of a2PI; t-PA, tissue plasminogen activator; XIIIa, activated coagulation Factor XIII.
glutaminase, activated blood coagulation Factor XIII (XIIIa) (2) (3) (4) . The a2PI thus cross-linked renders the fibrin clot more resistant to fibrinolysis. Particularly, the naturally occurring fibrinolytic process that occurs subsequently to fibrin formation and is caused by fibrin-associated plasminogen activation (5) is mainly inhibited by a2PI cross-linked to fibrin (6) .
a2PI serves only as a glutamine substrate for XIIIa in the cross-linking reaction (4) , and the cross-linking occurs between lysine residues of fibrin a-chains and a glutamine residue of the a2PI molecule that is the second residue from the NH2-terminal (4) .
We have previously suggested that the a2PI cross-linking reaction may be a reversible equilibrium reaction that is common to the general cross-linking reaction catalyzed by transglutaminases (7, 8) , since the a2PI-fibrinogen cross-linked complex could be dissociated to each of its components to reach a new equilibrium state when the isolated complex was incubated with XIIIa (9) . It is important to know if the a2PI cross-linked with fibrin could be released physiologically, because such a release of a2PI from fibrin would make the fibrin less resistant to the fibrinolytic process, thereby accelerating fibrinolysis.
In the present study we have demonstrated that a2PI once cross-linked with fibrin could be released by the function ofXIIIa and the release could result in an acceleration of fibrinolysis.
Methods
Plasma. Blood was withdrawn from a normal individual, a patient with congenital deficiency of a2PI (10) , or a patient with congenital deficiency of Factor XIII, into 0.1 vol of 3.8% sodium citrate or into 0.1 vol of 100 U/ml heparin. The blood was then centrifuged to prepare platelet-rich or -poor plasma. The concentration of a2PI in plasma was immunologically determined (2) .
Purified proteins. a2PI was purified from human plasma by the previously described method (1 1). The concentration was determined spectrophotometrically using El' = 7.03 at 280 nm (11). The protein was dissolved in Tris-buffered saline (0.05 M Tris-HCI, 0.15 M NaCl, pH 7.4). Human fraction 1-4, prepared according to the method of Blomback and Blomback (12) , was used as the fibrinogen preparation after removing contaminating plasminogen and plasma fibronectin from the preparation with lysine-Sepharose (13) and gelatin-Sepharose (14) , respectively. The concentration was determined spectrophotometrically using El' = 15.1 at 280 nm (12) and the coagulable protein was >95%. Factor XIII was purified from human plasma by the method described by Curtis and Lorand (15) . Factor XIII activity was assayed by the dansylcadaverine incorporation method as described by Lorand et al. (16) . 1 U of Factor XIII is defined as the activity of Factor XIII present in 1 ml normal pooled standard plasma. Thrombin-modified Factor XIII was prepared as described previously (4) and was converted to XIIIa by calcium ions added at the time of the experiments. Purified thrombin was prepared from a bovine thrombin preparation (Mochida Pharmaceuticals, Tokyo, Japan) according to the method ofLundblad (17) . The hirudin (a thrombin inhibitor obtained from leeches) used was a grade IV preparation from the Sigma Chemical Co., St. Louis, MO, and was shown to have no plasmin inhibitor activity when tested by the chromogenic ( 18) and clot lysis (19) methods. Tissue plasminogen activator (t-PA) was purified from the culture media of a human melanoma cell line according to the method of Rijken and Collen (20) . The t-PA activity was assayed by the clot lysis method using a calibration curve constructed with the WHO standard preparation kindly supplied by Dr. P. J. Gaffney, National Institute for Biological Standards and Control, London, England. Native Glu-plasminogen, whose amino-terminal group is glutamic acid, was prepared from fresh plasma in the presence of aprotinin (10 kallikrein inhibitor units/ml) (Mochida Pharmaceuticals) by affinity chromatography with lysine-Sepharose followed by DEAE-Sephadex chromatography (21) . Plasmin was prepared by activating plasminogen with urokinase-coupled Sepharose 4B (1 1). Plasmin activity was determined by the amidolytic method (22) using the chromogenic substrate, H-D-ValLeu-Lys-p-nitroanilide (S-2251; Daiichi Pure Chemicals Co., Tokyo, Japan).
NHrterminal peptide ofa2PI. The NH2-terminal 12-residue peptide of a2PI (N-peptide), Asn-Gln-Glu-Gln-Val-Ser-Pro-Leu-Thr-Gly-LeuLys-NH2. Ml of normal or a2PI-deficient heparinized plasma or buffered saline and incubated at 37°C. The suspending plasma contained aprotinin (10 U/ ml) and hirudin (10 U/ml) (Sigma Chemical Co.). The suspending buffered saline contained XIIIa (0-0.6 U/ml) and aprotinin (10 U/ml). As control experiments, EDTA (2 mM) and iodoacetamide (1 mM) were further included in the suspending media to inhibit XIIIa activity. During the incubation, aliquots of 20 Ml were removed from the suspending media at intervals for radioactive counting. Results were expressed as the percent release ofradiolabel from the clot, which was calculated from the counts, applying a correction for the influence ofrepeated subsampling on the volume. In some experiments, the release was also expressed as moles. The experiments were carried out in triplicate. To confirm the cross-linking of a2PI to fibrin and its subsequent release, the washed clot, together with buffered saline suspending the clot, was lyophilized as a whole before and after the incubation, then solubilized and subjected to sodium dodecyl sulfate (SDS)polyacrylamide gel electrophoresis. The washed clot was prepared from 100 Ml of normal citrated plasma or 100 ,l of fibrinogen (2.3 mg/ml) in Tris-buffered saline containing a2PI (30 Mg/ml) and Factor XIII (0.2 U/ml), but otherwise all the other conditions were the same as described above. The solubilization was carried out by incubation for 20 min at 100°C with 40 Al of 10% SDS, 4 M urea, 10% mercaptoethanol. The dissolved samples were subjected to the electrophoresis on a slab gel or disc gel according to the procedures of Laemmli (23) using a 7.5% separating gel and a 4% stacking gel. High molecular weight standards (Bio-Rad Laboratories) were run in parallel. After the electrophoresis, the gels were stained with Coomassie Brilliant Blue and destained by diffusion. The a2PI was identified by radioautography by exposing the dried slab gel to X-ray film (Lo-dose film; E. I. Du Pont de Nemours & Co., Wilmington, DE) in the presence of intensifying screens (Lo-dose/2 mammography intensifying screen; E. I. Du Pont de Nemours & Co.) for 24 h at -70'C. The a2PI was also identified by cutting the disc gel transversely into slices of 3 mm thickness and counting each slice for radioactivity. a2PI released was examined for its antiplasmin activity. For that purpose, 2 ml of normal plasma containing radiolabeled a2PI was clotted, washed, suspended, and incubated in 2 ml of buffered saline containing 0.6 U/ml XIIIa in the same way as described above, except for the omission of aprotinin. At 20 and 60 min of incubation, aliquots of 800 or 2 M1 were removed from the suspending media for antiplasmin activity or radioactive counting, respectively. For antiplasmin activity an aliquot of 800 Ml was mixed at 370C with 200 Al of 5 mM S-2251 and then with 100 ul of plasmin solution (4 nmol of substrate hydrolyzed/second per ml). Increase of absorbance at 405 nm was monitored by a DU-8 spectrophotometer (Beckman Instruments, Inc., Fullerton, CA), and the immediate-type antiplasmin activity was calculated as described previously (18) using a standard curve constructed with normal plasma and expressed as a percent of the standard normal plasma.
Incorporation ofa2PI to clot. The washed clot prepared from 100 Ml of normal plasma was suspended and incubated at 370C in 500 ,l of a2PI-deficient heparinized plasma supplemented with various concentrations of a2PI containing a trace amount of radiolabeled a2PI. The suspending plasma contained aprotinin (10 U/ml) and hirudin (10 U/ ml). As control experiments, EDTA (20 mM) and iodoacetamide (1 mM) were further included in the suspending plasma. After various lengths of incubation, the clot was removed, washed, and counted for radioactivity. The amount of a2PI incorporated into the clot from the suspending plasma was calculated from the count of the clot and the specific radioactivity of a2PI used. Measurement offibrinolysis. 2 ml of platelet-rich plasma were mixed with 10 Ml of radiolabeled fibrinogen. A 180 Ml aliquot of this mixture was mixed and incubated with 20 ,ul of calcium chloride (250 mM). The clot soon formed and underwent retraction. After incubation at 37°C for 30 min, the clot was suspended by the addition of 800 M1 of plateletpoor plasma containing t-PA (8.4 U/ml), hirudin (1 U/ml) and various concentrations of the NH2-terminal 12-residue peptide of a2PI (N-peptide) and was further incubated at 37°C for as long as 20 h. The purpose of including hirudin in the suspending plasma milieu was to prevent the suspending plasma from being clotted by thrombin released from the clot. In another set of experiments, t-PA was added to plasma before clotting, and the clot formed was washed and suspended in buffered saline containing plasminogen. 2 Ml of t-PA (4,200 U/ml) was added to a 180-Ml aliquot of the platelet-poor plasma containing radiolabeled fibrinogen, and the plasma was clotted with 10 ,ul of calcium chloride (500 mM) and 10 ,l of thrombin (20 U/ml). After incubation for 30 min at 37°C, the clot was first squeezed with a stick against the wall of the tube to express as much fluid as possible, washed three times by soaking it in I ml ofTris-buffered saline containing 2% ofalbumin (Trisbuffered albumin saline) for 5 min at room temperature each time, and then finally suspended and incubated in I ml of Tris-buffered albumin saline containing Glu-plasminogen (0.18 mg/ml), calcium chloride (2.5 mM), and XIIIa (1.8 U/ml). As control experiments, EDTA (25 mM) and iodoacetamide (1 mM) were included in addition to plasminogen in Tris-buffered albumin saline to inhibit XIIIa activity. The mixture containing the suspended clot was further incubated at 37°C. To measure fibrinolysis, 20 ,l aliquots of the suspending plasma or buffered saline were removed at intervals for counting of radioactivity. Results were expressed as the percent release of radiolabel (radiolabeled fibrin degradation products, I25I-FDP), which was calculated from the counts, applying a correction for the influence of repeated subsampling upon the volume of the supernatant.
Results
Release ofa2PIfromfibrin clot catalyzed by XIIIa. Normal citrated plasma containing radiolabeled a2PI was clotted by an addition of calcium chloride. a2PI was rapidly cross-linked to fibrin by XIIIa generated during the coagulation. After 30 min incubation at 370C, the clot formed was squeezed and washed to remove unbound materials. The clot was then suspended and incubated in a2PI-deficient plasma or buffered saline. Aprotinin was present during the entire procedure to inhibit fibrinolysis. Hirudin was present in the suspending plasma to prevent the plasma from being clotted by any thrombin that remained bound to fibrin.
As seen in Fig. 1, a2PI was gradually released upon incubation from the fibrin clot into the suspending plasma or buffered saline. When EDTA and iodoacetamide were present in the suspending media to inhibit XIIIa, the release was significantly lower and very small. The degree of release of a2PI was nearly the same whether the fibrin clot was suspended in a2PI-deficient plasma or in buffered saline (Fig. 1) . Similar degrees ofrelease may have been caused by similar amounts of XIIIa operating in both experiments. XIIIa operating in both experiments without addition of XIIIa was the XIIIa that was activated during the coagulation and remained bound to fibrin in the washed fibrin clot (24). There was no supply of XIIIa from the suspending plasma because activation of Factor XIII in the suspending plasma was inhibited by the presence of hirudin. However, the release of a2PI was accelerated when XIIIa was added to the buffered saline (Fig. 1) . The acceleration was found to be dependent on the amount of XIIIa added. The release observed during the initial 1-h incubation is shown in Fig. 2 .
Cross-linking and subsequent release were confirmed by SDSpolyacrylamide gel electrophoresis of the washed clots. In autoradiography of the polyacrylamide slab gels, there appeared a distinct radioactive band corresponding to free a2PI after the incubation of the washed clots for 4 h in buffered saline containing XIIIa (Fig. 3) . Radiocounting of the sliced disc gels revealed that only a small proportion of a2PI remained unbound and most of a2PI were present in a form covalently bound to polymerized cross-linked fibrin a-chains before the incubation (Fig. 4) . After the incubation there was a remarkable increase of the height of the radioactive peak corresponding to free a2PI (Fig. 4) . The increase ofthe radioactivity of free a2PI was around 25 or 22% ofthe total radioactivity in a purified fibrin clot system or in a plasma clot system, respectively.
The released a2PI had the inhibitor activity similar to that of the original a2PI. As shown in Fig. 5 antiplasmin activity was gradually released on incubation from the washed plasma clot. The presence of iodoacetamide and EDTA suppressed the release. The release ofthe inhibitor activity was parallel to the release of the radioactivity; at 60 min incubation in Fig. 5 the total radioactivity released was also -4% of the total radioactivity present in the original plasma.
When the clot was suspended in the medium containing a2PI, some of the a2PI present in the suspending medium were incorporated into the clot by XIIIa in exchange for the release of fibrin-bound a2PI. The washed clot prepared from normal plasma was suspended and incubated in the a2PI-deficient plasma supplemented with various amounts of a2PI. The release and A B Fig. 6 indicate that the net release of a2PI from the clot was decreased when the concentration Of a2PI in the suspending plasma was increased. It also indicates that the net release was nearly zero when the concentration of a2PI in the suspending plasma was the same as that of the plasma from which the clot had been prepared. Acceleration ofa2PI release by N-peptide. The washed fibrin clot was prepared as described above from normal plasma containing radiolabeled a2PI. The clot was suspended and incubated in normal heparinized plasma with or without the presence of N-peptide.
As seen in Fig. 7 , radiolabeled a2PI was gradually released from the fibrin clot on incubation. Here again, the release was suppressed by the presence of EDTA and iodoacetamide which 4- ficient plasma and normal plasma (A, a2PI 0.4 MM), and normal plasma (-, a2PI 0.8 MM). The suspending plasmas were heparinized ones and contained aprotinin.
For the measurement of the release, the normal plasma containing a trace amount of radiolabeled a2PI was used for preparation of the washed clot. For the measurement of the incorporation, the normal plasma containing a fixed amount of radiolabeled a2PI was used for preparation of the suspending plasma milieus. The net release was calculated by subtracting the value of the incorporation from the value of the release. For details, see Methods.
inhibit XIIIa. The release was increased by the presence of Npeptide (Fig. 7) , and the increase was dependent on the concentrations of N-peptide (Fig. 8) .
Acceleration ofIibrinolysis by the release ofa2PIfromjibrin
clot. Normal plasma containing radiolabeled fibrinogen and exogenously added t-PA was clotted by adding thrombin and calcium chloride. After incubation for 30 min at 37°C the clot formed was squeezed and washed to remove unbound materials. The clot retained the t-PA adsorbed onto fibrin. The clot was then suspended and incubated in buffered saline containing plasminogen. The suspending buffered saline additionally contained XIIIa or EDTA/iodoacetamide. Fibrinolysis was followed by counting of the radioactivity released into the suspending buffered saline at time intervals. As seen in Fig. 9 , fibrinolysis was accelerated when XIIIa was present in the suspending buffered saline as compared with the fibrinolysis observed in the presence of EDTA/iodoacetamide. The release of a2PI in these experiments was measured using radiolabeled a2PI instead of radiolabeled fibrinogen, as in Fig. 2 , in which fibrinolysis was suppressed by aprotinin. Approximately 20% of the a2PI bound to fibrin was released after 2 h of incubation in the presence of exogenously added XIIIa, expressed as a percentage of the total radioactivity, as in Fig. 1 . The release in the presence of EDTA/iodoacetamide was subtracted. The abscissa is on a logarithmic scale.
whereas the release was only <1% in the presence of EDTA/ iodoacetamide which inhibited XIIIa endogenously generated in the clot.
When an a2PI-deficient plasma clot was used instead of a normal plasma clot in the experiments of Fig. 9 , the lysis was very rapid and completed in less than 1 h. Furthermore, there was no difference of fibrinolysis whether EDTA/iodoacetamide was added or not, in contrast to a significant difference observed with the normal plasma clot in Fig 9. This indicates that EDTA/ iodoacetamide did not influence the fibrinolytic process itself, at least under the experimental conditions used.
Normal platelet-rich plasma containing radiolabeled fibrinogen was clotted by the addition of calcium chloride. After 30 min of incubation at 370C, the retracted clot was suspended in normal plasma containing a fixed amount ofexogenously added t-PA and various concentrations of N-peptide and was then further incubated at 370C. Fibrinolysis was followed by counting of the radioactivity released into the suspending plasma at time intervals.
As seen in Fig. 10 , fibrinolysis was accelerated by the presence of N-peptide, and the acceleration was dependent on the concentrations ofN-peptide. The rate offibrinolysis was nearly proportional to the degree of the release of a2PI achieved by Npeptide at the end of 2 h of incubation (Fig. 1 1) . The extent of 100 A Figure 9 . Acceleration of fibrinolysis by the release of a2PI. release at the end of 2 h of incubation represents nearly the maximum release achieved by each concentration ofN-peptide, since the cumulative release reached a plateau at around 2 h of incubation. This indicates that the maximum extent of release which was achieved during the initial 2 h of incubation determined the rate of the following fibrinolytic process seen in Fig.  10 . When a2PI-deficient plasma or XIII-deficient plasma was used instead of normal plasma in similar experiments, no acceleration of fibrinolysis was observed in the presence of N-peptide (Fig. 12) . Discussion a2PI is cross-linked to the fibrin a-chain when blood coagulation takes place (2-4). The reaction proceeds rapidly to reach a maximum and then levels off, with only around 20% of the a2PI being cross-linked (2). We have suggested that this self-limiting nature of the cross-linking reaction may be due to the reaction equilibrium favoring dissociation of the cross-linked complex rather than the development of structural hindrance in the polymerizing fibrin(ogen) (9) . The concept is mainly based on the observation that the a2PI-fibrinogen cross-linking reaction is a reversible one, and the isolated complex of a2PI and fibrinogen could be dissociated rapidly into each ofits components by XIIIa Release of o2PI 1%)
The extents of fibrinolysis in the presence of various concentrations of N-peptide, corresponding to those in Fig. 8 , are those achieved at the incubation times indicated at the end of each line and adopted from the data in Fig. 10 . 16 20 suspended, and incubated in Incubation Time (hours) platelet-poor a2PI-or Factor XIII-deficient plasma containing various concentrations of N-peptide, respectively. The experimental conditions were the same as those in Fig. 10 , except for the omission of t-PA in a2PI-deficient plasma. The concentrations of N-peptide were 500 (o) and 100 AM (o) . Control without N-peptide (.).
After various lengths of incubation, cumulative release of radiolabel from the clot into the suspending plasmawas measured and expressed, as in Fig. 10 . (9) . In the present study, we have extended our investigation further to see if the a2PI-fibrin cross-linking reaction is also a reversible one. The question is crucial because a2PI may be mainly cross-linked to fibrin and not much with fibrinogen when a thrombus is formed in vivo, and dissociation of the a2PI-fibrin cross-linked complex would be of great consequence in thrombolysis.
When the fibrin clot prepared from normal plasma was suspended and incubated in a2PI-deficient plasma or buffered saline, a2PI which had been cross-linked to fibrin was gradually released from the fibrin clot (Fig. 1) . The release was most likely mediated by XIIIa since the rate of the release was dependent on the amount of XIIIa present (Fig. 2 ) and the release was suppressed by the presence of EDTA and iodoacetamide ( Fig. 1 ) which are known to inhibit XIIIa (25, 26) . The release progressed very slowly and took hours to level off (Fig. 1) . This slow progress of the release is in contrast to the very rapid dissociation of the a2PI-fibrinogen complex which was completed in only a few minutes (9) . The difference may be explained by the structural tightness ofthe cross-linked fibrin clot which hinders the enzyme (XIIIa) from gaining access to the substrate a2PI-fibrin complex. The release slowed down after 2 h ofincubation, and every effort to accelerate the release, including frequent changes of the suspending media and replenishment of fresh XIIIa, was unsuccessful. We speculate that the highly polymerized a-chain of fibrin formed after 2 h of incubation may have hindered the release. We have previously shown that the a2PI-a-chain monomer complex formed at the initial stage ofclotting was gradually transformed to the a2PI-a-chain polymer complex as the achain cross-linking polymerization proceeded (3, 9) . This was also seen in the present study (Fig. 4 B) . The transformation was completed after 2 h of incubation and no a2PI-a-chain monomer complex was left (3). Probably XIIIa could gain access to the a2PI cross-linked to a-chain monomer, but not to the a2PI cross-linked to a-chain polymer.
When a2PI was present in the suspending medium, some of the a2PI was incorporated by XIIIa into the clot in exchange for the release of fibrin-bound a2PI (replacement) and the incorporation was proportional to the concentration of a2PI in the suspending medium. Therefore, the net release of a2PI from the suspended clot was inversely related to the concentrations of free a2PI in the suspending medium (Fig. 6) . When the concentration of a2PI in the suspending medium was the same as that of the original plasma from which the clot had been prepared, the net release was nearly zero, since the incorporation and the release were balanced (Fig. 6) .
XIIIa is classified as a transglutaminase and is also called plasma transglutaminase (27) . The findings in the present and previous studies that a2PI could be released from the a2PI-fibrin(ogen) complex by XIIIa are in accordance with and fully expected from the general reaction mechanism for transglutaminases proposed by Folk (7) and Chung and Folk (8) and reviewed by Lorand and Conrad (28) .
N-peptide, which contains the residue involved in the crosslinking reaction with fibrin(ogen), was shown to be rapidly crosslinked with fibrin, and competitively inhibits the cross-linking of a2PI with fibrin when it is present concurrently with a2PI at the time ofclotting in a purified system (29) as well as in plasma (30) . When the preformed fibrin clot containing radioactive a2PI cross-linked with fibrin was suspended in normal plasma, the fibrin-bound a2PI was replaced by free a2PI present in the suspending plasma, and radioactive a2PI was gradually released from the fibrin clot (Fig. 7) . This replacement ofthe bound a2PI was most likely mediated by XIIIa because EDTA and iodoacetamide inhibit the release (Fig. 7) . When the N-peptide was present in the suspending plasma, further replacement of the bound a2PI by N-peptide occurred, and the release was increased (Fig. 7) . The increase was dependent on the concentrations of N-peptide (Fig. 8) , which was incorporated into the clot in exchange for a2PI.
In the previous studies, a2PI cross-linked with fibrin was shown to play a significant role in inhibition of physiologically occurring fibrinolysis, thus stabilizing thrombi, including hemostatic plugs (6) , although the amount of a2PI cross-linked to fibrin is very small and only 1 mol/20 mol of fibrin (monomer). The importance of cross-linking of a2PI with fibrin was further supported by the previous finding that the presence ofN-peptide in plasma at the time of clotting accelerated the subsequent fibrinolytic process by inhibiting the cross-linking of a2PI (30) and the extent of fibrinolysis was found to be proportional to the degree of inhibition of a2PI cross-linking (30) . In the present study, it was further demonstrated that the release of a2PI from the fibrin clot results in an acceleration of fibrinolysis.
Normal plasma supplemented with t-PA was clotted in the presence of calcium ions and incubated at 370C for 30 min, during which the cross-linking of a2PI with fibrin was completed, but no significant fibrinolysis took place. The fibrin clot thus prepared was suspended in buffered saline containing plasminogen. When the suspending buffered saline contained XIIIa in addition and the release of a2PI from the fibrin clot was accelerated, as seen in Fig. 2 , the fibrinolysis was significantly accelerated ( Fig. 9) as compared with the control where XIIIa was suppressed be EDTA/iodoacetamide and the release ofa2PI was negligibly small (Fig. 2) . The retracted plasma clot prepared from normal plateletrich plasma in the presence of calcium ions was suspended in normal plasma containing a fixed amount ofexogenously added t-PA and various concentrations of N-peptide. The presence of N-peptide in the suspending plasma accelerated fibrinolysis (Fig.  10) , and the rate of fibrinolysis was proportional to the amount of the a2PI released (replaced) by N-peptide (Fig. 1 1) . The acceleration was not seen when a2PI-deficient or XIIIa-deficient plasma was used (Fig. 12) , indicating that the acceleration was caused by the XIIIa-catalyzed release of a2PI from fibrin. When the nonretracted plasma clot prepared from platelet-poor plasma was suspended in plasma containing N-peptide, the acceleration caused by N-peptide was not so remarkable as that seen with the retracted plasma clot. As has been suggested in the previous study (6) , inhibition of fibrinolysis of a retracted plasma clot may be more dependent on a2PI bound to fibrin as compared with a nonretracted plasma clot, and the reduction ofthe amount of fibrin-bound a2PI by N-peptide may have produced a more pronounced effect on the fibrinolysis of the retracted clot than on the fibrinolysis of the nonretracted clot.
All the findings presented here may be extrapolated to in vivo situations. Under thrombolytic therapy with urokinase or streptokinase, a2PI is consumed by forming a complex with generated plasmin and being removed from the circulation (19, 31) . Consequent reduction of a2PI level in the circulation has been considered to be unfavorable because it may induce a generalized hemorrhagic tendency. However, the reduction of a2PI level might also bring about some beneficial effects in view of thrombolysis (32) because the reduction of a2PI level would facilitate the release of a2PI from thrombi as seen in Figs. 1 and 6, when thrombi are fresh and fibrins are not highly cross-linked, thus accelerating spontaneously occurring fibrinolysis. This is likely to occur since more XIIIa may be continuously generated on the surface ofthrombi in in vivo situations as compared with the in vitro situations employed in the present study where XIIIa generation was limited. In fact, Kumada and Abiko demonstrated that reduction of a2PI level in the circulation induced spontaneous thrombolysis in animal experiments (33) . They experimentally produced thrombi in rats. After development of thrombi, the a2PI level in the circulation was reduced and maintained at <50% of normal by repeated injections of anti-a2PI F(ab)2. The average size of thrombi of the rats whose a2PI level had been reduced was significantly smaller than that ofthe controls and approximately half of the control values. Moreover, the average size of thrombi was significantly smaller than the initial size of thrombi observed at the start of treatment with anti-a2PI; the average size was approximately two-thirds of the initial size. Significantly higher levels of FDP were observed in the anti-a2PI treated group. These findings indicated that reduction of a2PI level in the circulation induced spontaneous thrombolysis, thereby not only preventing the growth ofthrombi but also accelerating the dissolution of thrombi already formed. Probably the reduction of a2PI level induced the release Pf a2PI from thrombi and facilitated the spontaneously occurring fibrinolysis.
The results of the present study may imply that the rapid and sustained reduction of a2PI level in the circulation by pharmacological or any other means, if possible, would cause the release of a2PI from thrombi and facilitate thrombolysis induced by the physiologically occurring fibrinolytic process or exogenously administered plasminogen activators.
